Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Jun 14, 2020 9:00 AM - Jun 18, 2020 5:00 PM

(Eastern Standard Time)

Fort Washington, PA 19034

DIA 2020 Global Annual Meeting

Quantitative Benefit-Risk Assessment: What Methods are Being Used? How Far has Industry Come?

Session Chair(s)

Meredith  Smith, PhD, MPA, FISPE

Meredith Smith, PhD, MPA, FISPE

Senior Director, Implementation Science Pillar Lead

Evidera, Inc, United States

This session will describe the results of a recently conducted industry-wide survey on the use of quantitative benefit-risk assessment (qBRA) methods within life science companies. In particular, it will describe whether and to what extent such methods are being utilized, what are the types of qBRA methods being utilized, challenges to implementing qBRA within these organizations, and strategies for overcoming those challenges.

Learning Objective : Describe when, why and to what extent qBRA is being adopted within different life science companies to inform decision making; Describe the range of frameworks and methods being utilized within life science companies to implement qBRA; Identify the challenges to introducing qBRA within life science companies and ways that these have been overcome, including factors to facilitate successful implementation.

Speaker(s)

Kevin  Marsh, PhD, MSc

When, Why, and to What Extent qBRA is Being Adopted Within Different Lifescience Companies to Inform Decision Making?

Kevin Marsh, PhD, MSc

Evidera, United Kingdom

Vice President, Patient-Centered Research

Brett  Hauber, PhD, MA

What Are the Types of Benefit-Risk Assessment Frameworks Being Used Within the Pharmaceutical Industry Currently and What are the Range of qBRA Methods Being Employed?

Brett Hauber, PhD, MA

Pfizer Inc, United States

Senior Director, Patient Preference Elicitation

Rachael L. DiSantostefano, PhD, MS

What Are the Challenges to Introducing qBRA Within Lifescience Companies and Ways that These Have Been Overcome?

Rachael L. DiSantostefano, PhD, MS

Janssen Research & Development, LLC, United States

Senior Director, Epidemiology

Meredith  Smith, PhD, MPA, FISPE

Future Directions for Use of qBRA

Meredith Smith, PhD, MPA, FISPE

Evidera, Inc, United States

Senior Director, Implementation Science Pillar Lead

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.